Arcellx hits record high as Gilead agrees to up to $7.8 bln acquisition

Arcellx

23/02/2026 17:55

Updates

** Shares of cancer therapy developer Arcellx ACLX.O surge 77.5% to all-time-high of $113.81

 ** Arcellx on track for biggest pct gain and set to add about $2.87 billion in market value, if gains hold

** Gilead Sciences GILD.O says it will buy ACLX for an implied equity value of $7.8 billion

** "Arcellx represents a clear strategic fit for Gilead's business, simplifying what was a long-standing and increasingly complex partnership ahead of a critical commercial launch for the company," said BMO Capital Markets analyst

** The offer includes $115 per share in cash and one contingent value right of $5 per share

** Shares of GILD were down 1%

** Up to last close, ACLX stock had fallen 1.7% YTD

(Reporting by Puyaan Singh and Kamal Choudhury)

((Puyaan.Singh@thomsonreuters.com))